A guide to the FDA Purple Book: what it lists under PHS Act section 351(k)(9) (licensed biological products, reference products, biosimilars, interchangeables, exclusivity dates and the patent lists added by the 2020 law), how to search it step by step, a Purple Book vs Orange Book table, and what interchangeability means. It closes with the facility side of licensure: 21 CFR 601.20(d), Atlas inspection outcomes by FDA program from January 2025 to October 2026 (vaccine facilities 51.1% VAI, 0 of 47 OAI; drug quality 15.7% OAI), complete response letter counts by application type, and named biologics facility records.